Amplifon (OTCMKTS:AMFPF) versus Biodesix (NASDAQ:BDSX) Head to Head Contrast

Amplifon (OTCMKTS:AMFPF) and Biodesix (NASDAQ:BDSX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Volatility and Risk

Amplifon has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Biodesix has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Amplifon and Biodesix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amplifon	0	1	2	0	2.67
Biodesix	1	0	5	0	2.67

Biodesix has a consensus target price of $32.50, indicating a potential upside of 226.31%. Given Biodesix’s higher probable upside, analysts clearly believe Biodesix is more favorable than Amplifon.

Valuation and Earnings

This table compares Amplifon and Biodesix”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amplifon	$2.61 billion	0.85	$157.31 million	$0.56	18.01
Biodesix	$88.50 million	1.14	-$35.26 million	($4.85)	-2.05

Amplifon has higher revenue and earnings than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Amplifon, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Amplifon and Biodesix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amplifon	4.74%	14.28%	3.89%
Biodesix	-39.85%	-1,760.83%	-40.28%

Institutional and Insider Ownership

21.0% of Biodesix shares are held by institutional investors. 30.1% of Biodesix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Amplifon beats Biodesix on 8 of the 13 factors compared between the two stocks.

About Amplifon

Amplifon S.p.A. engages in the distribution of hearing solutions and the fitting of customized products that help people rediscover various emotions of sound in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Ampli-easy, Ampli-connect, Ampli-energy, and Ampli-mini hearing devices. It also operates Ampli-care, a platform to deliver audiological care experience; and Amplifon App to manage the device functions in real-time directly from smartphone. Amplifon S.p.A. was founded in 1950 and is headquartered in Milan, Italy. Amplifon S.p.A.

About Biodesix

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.